Videos

According to Yoanna S. Pumpalova, MD, both early-onset and later-onset colorectal cancers are genetically similar in terms of somatic mutations.

Venlafaxine was found to be an effective treatment for patients with breast cancer who are experiencing vasomotor symptoms.

Two genitourinary oncologists discussed research examining germline platelet polygenic risk scores to predict survival outcomes in kidney cancer.

It’s unlikely guidelines recommend screening patients younger than 45 years for colorectal cancer, according to Yoanna S. Pumpalova, MD.

Patients with high-risk or intermediate-risk disease may benefit from allogeneic stem cell transplantation as a potentially “curative approach.”

In this segment, Dr. Devarakonda asks Dr. Singhi to address how route of administration and treatment logistics influence clinical decision making in EGFR mutated metastatic non-small cell lung cancer.

In this segment, Dr. Devarakonda asks Dr. Rotow to move beyond clinical trial data and discuss the real world factors that influence first line treatment selection in EGFR mutated metastatic non-small cell lung cancer.

The NHS-Galleri study showed that multi-cancer screening with the Galleri test did not reduce the number of cancers found at stage III or IV.

The addition of Bacillus Calmette-Guérin to ERBT significantly reduced 1-year recurrence rates among patients with high-risk, muscle-invasive disease.

Ben Brewer, PsyD, discussed the 5 core components of cognitive behavioral therapy for insomnia.

Donor availability may influence the treatment decision-making process regarding the use of transplantation for those with myelofibrosis.

Team Roswell presents ABC Consortium real-world data from 15 US centers comparing second-line outcomes with axi-cel, liso-cel, and a third CAR T product in large B-cell lymphoma, including manufacturing timelines, bridging therapy, response, survival, and key toxicities. The discussion highlights faster vein-to-vein time and fewer out-of-spec products with axi-cel, broadly similar efficacy between axi-cel and liso-cel, and higher rates of cytokine release syndrome/neurotoxicity with axi-cel alongside lower acute toxicity with liso-cel. Team NYC cross-examines the interpretation, especially the limited sample for the third product, and the panel pivots to practical post–CAR T survivorship issues like infections, hypogammaglobulinemia, IVIg use, and the need for more standardized supportive-care practices.

Julian Hong, MD, MS, stated that the demand for highly specialized teams trained to combat the onset of mental health disorders outpaces the supply.

FcRH5 is emerging as a potentially highly active target for cellular therapies in multiple myeloma care, said Natalia Neparidze, MD.

According to a study published in Cancer, new-onset mental health disorders increased the risk of all-cause mortality in patients with cancer.

Adverse effects of novel immunotherapies appear controllable compared with chemotherapy in hematologic malignancies, according to Guenther Koehne, MD.

Newer generations of BTK inhibitors may have fewer cardiac toxicities compared with earlier iterations, according to Nicole Lamanna, MD.

Julia E. McGuiness, MD, discussed the timeline for mammographic density changes following significant weight loss.

Scott Tagawa, MD, MS, FACP, FASCO, evaluated how the rPFS improvement with lutetium 177 could help integrate the treatment into the frontline metastatic HSPC setting.

Treatment with rusfertide appears to reliably control hematocrit among those with polycythemia vera, according to Andrew Kuykendall, MD.

Oliver Sartor, MD highlighted SBRT, hormonal therapy, and the PSMA-DC regimen for patients with biochemical recurrence and PSMA-PET–positive disease.

Yan Leyfman, MD, discussed the factors that may ultimately define the next era of transplant medicine across hematologic malignancies.

Among patients who discontinued enfortumab vedotin due to an ongoing response or toxicity, 57% were treatment-free and alive 1 year later.

In this segment, Dr. Devarakonda asks Dr. Rotow to outline the advantages and limitations of combination regimens compared with single agent EGFR tyrosine kinase inhibitors in the first line treatment of EGFR mutated metastatic non-small cell lung cancer.

Panelists review a patient with DLBCL relapsing 8 months after frontline Pola-R-CHP following an initial complete response. With low symptom burden and favorable performance status, the debate centers on optimal second-line strategy, outpatient CAR T feasibility, caregiver limitations, and balancing treatment intensity with quality-of-life and employment considerations in an urban setting.

In this segment, Dr. Devarakonda invites the panel to reflect on how updated clinical guidelines are shaping first line treatment patterns in EGFR mutated metastatic non-small cell lung cancer.

Acalabrutinib/venetoclax may offer less toxicity compared with other therapies in chronic lymphocytic leukemia, said Nicole Lamanna, MD.

Faculty analyze a primary refractory, high-intermediate–risk DLBCL case with persistent PET-positive disease after frontline R-CHOP and symptomatic progression. Discussion focuses referral for second-line CAR T and how rural geography and distance from a CAR-T center influence logistics. Panelists weigh aggressive disease biology against access barriers and caregiver availability in determining next steps.

According to Sebnem Ece Eksi, PhD, sympathetic signals led to shifts in cancer-associated fibroblasts to a more inflammatory state.

Findings from a study published by Sebnem Ece Eksi, PhD, and coauthors found that sympathetic nerves affect cancer-associated fibroblasts in a way that remodels the tissue environment.